Estimaciones de analistas de Wall Street para Aytu BioPharma, Inc. (AYTU): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 5 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-09-29 | $-0.29 | ||
| 2026-05-13 | $-0.53 | $-0.31 | -71.0% |
| 2026-02-03 | $-1.05 | $-0.26 | -303.8% |
| 2025-11-13 | $-0.08 | $-0.06 | -33.3% |
| 2025-09-23 | $-2.92 | $-0.02 | -14500.0% |
| 2025-05-14 | $0.20 | $-0.17 | +217.6% |
| 2025-02-12 | $-0.28 | $-0.28 | +0.0% |
| 2024-11-13 | $-0.20 | $-0.34 | +41.2% |
Ratios de valoración
| Precio / Valor contable | 0.58 |
| EV / EBITDA | -0.73 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $2.6M | $3.2M | $3.7M | $7.3M | $27.6M | $65.6M | $96.7M | $107.4M | $65.2M | $66.4M |
| Coste de Ventas | $957076 | $1.4M | $2.1M | $2.2M | $8.3M | $36.4M | $46.4M | $40.8M | $16.1M | $20.6M |
| Beneficio Bruto | $1.6M | $1.8M | $1.6M | $5.1M | $19.4M | $29.2M | $50.3M | $66.6M | $49.1M | $45.8M |
| I+D | $6.3M | $1.3M | $167595 | $589072 | $1.7M | $5.6M | $12.7M | $4.1M | $2.8M | $1.3M |
| Generales y Administrativos | $8.8M | $17.6M | $17.7M | $19.2M | $31.1M | $55.8M | $69.9M | $70.1M | $42.0M | $38.3M |
| Gastos Operativos | $15.8M | $20.7M | $19.5M | $22.0M | $40.5M | $88.1M | $160.2M | $83.7M | $50.6M | $53.7M |
| Beneficio Operativo | -$21.7M | -$20.1M | -$19.7M | -$16.8M | -$21.1M | -$58.9M | -$109.9M | -$17.1M | -$1.6M | -$7.8M |
| EBITDA | -$21.8M | -$18.1M | -$15.3M | -$14.6M | -$12.2M | -$29.0M | -$28.0M | -$3.3M | $1.4M | -$4.7M |
| Gastos por Intereses | $5.5M | $2.5M | $749423 | 0 | 0 | 0 | $147.5M | $5.0M | $4.8M | $3.7M |
| Beneficio Antes de Impuestos | -$28.2M | -$22.5M | -$10.2M | -$27.1M | -$13.6M | -$58.0M | -$108.9M | -$17.1M | -$10.4M | -$13.7M |
| Impuestos | 0 | 0 | 0 | $20.0M | 0 | $259000 | -$110000 | 0 | $2.1M | $437000 |
| Beneficio Neto | -$28.2M | -$22.5M | -$10.2M | -$47.2M | -$13.6M | -$58.3M | -$108.8M | -$17.1M | -$15.8M | -$13.6M |
| BPA | $-1294738.36 | $-193194.38 | $-3061.23 | $-1210.28 | $-60.20 | $-69.60 | $-74.01 | $-5.11 | $-2.86 | $-2.16 |
| BPA Diluido | $-1294738.36 | $-193194.38 | $-3061.23 | $-1210.28 | $-60.20 | $-69.60 | $-74.01 | $-5.11 | $-2.86 | $-2.16 |
| Acciones en Circulación (Diluidas) | $22 | $117 | $3328 | $38972 | $230000 | $840000 | $1.5M | $3.3M | $5.5M | $6.3M |
Precio
| Precio | $1.97 |
| Capitalización | $21M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADAP · ALUR · ANL · BFRI · EKSO · GOVX · NVNO
Explorar sector: Healthcare · Drug Manufacturers - Specialty & Generic
Más secciones de AYTU: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones